Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet 394:29–38. https://doi.org/10.1016/S0140-6736(19)31240-1
Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630–1642. https://doi.org/10.1016/S1470-2045(20)30525-8
CAS Article PubMed Google Scholar
Voorhees PM, Investigators for the GT, Kaufman JL, Laubach J, Investigators for the GT, et al (2020) ;136:936–45. https://doi.org/10.1182/BLOOD.2020005288
Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S et al (2018) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32:102–110. https://doi.org/10.1038/LEU.2017.179
CAS Article PubMed Google Scholar
Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H et al Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance. Scientific Reports 2020;10. https://doi.org/10.1038/S41598-020-62885-0
Jin F, Kumar S, Dai Y (2019) The adverse double-hit effect of combining cytogenetic abnormalities and ISS stage III on the outcome of patients with newly-diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 19:e68. https://doi.org/10.1016/J.CLML.2019.09.107
Singh C, Panakkal V, Sreedharanunni S, Jandial A, Jain A, Lad D et al Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World. Clin Lymphoma Myeloma Leuk 2022. https://doi.org/10.1016/J.CLML.2022.03.005
Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M et al (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34:1875–1884. https://doi.org/10.1038/S41375-020-0711-6
CAS Article PubMed PubMed Central Google Scholar
Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P et al (2021) Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol 39:757–767. https://doi.org/10.1200/JCO.20.02259
CAS Article PubMed Google Scholar
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398:314–324. https://doi.org/10.1016/S0140-6736(21)00933-8
CAS Article PubMed Google Scholar
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397:2361–2371. https://doi.org/10.1016/S0140-6736(21)00592-4
CAS Article PubMed Google Scholar
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D et al (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396:186–197. https://doi.org/10.1016/S0140-6736(20)30734-0
CAS Article PubMed Google Scholar
Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114:522–525. https://doi.org/10.1182/BLOOD-2008-12-193458
CAS Article PubMed Google Scholar
Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al (2010) Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leuk 2010 24:3. https://doi.org/10.1038/leu.2009.273
Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S et al (2013) Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leuk 2013 27:12. https://doi.org/10.1038/leu.2013.152
留言 (0)